US FDA to review biologics license application resubmission for Kevzara
Sanofi and Regeneron Pharmaceuticals have resubmitted their Biologics License Application for Kevzara, which is an investigational human monoclonal antibody to be used for treatment of rheumatoid arthritis (RA) with adult patients.